Pediatric Narcolepsy: Addressing the Challenges in Its Recognition, Diagnosis, and Management

Pediatric Narcolepsy: Addressing the Challenges in Its Recognition, Diagnosis, and Management

ReachMD Healthcare Image
RestartResume

Pediatric and adult narcolepsy are the same condition, but symptom presentation differs in children. Find out how and get key management strategies.  

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Half of children who develop narcolepsy do so before age 16. However, the majority do not get diagnosed in childhood. In fact, many children are misdiagnosed and, as a result, are medically treated for conditions they do not have. Join Drs. Thorpy and Morse as they delineate the differences between adult and pediatric narcolepsy and offer strategies to optimize treatment adherence and outcomes in children. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Michael J. Thorpy, MD

    Director, Sleep‐Wake Disorders Center
    Montefiore Medical Center
    Professor of Neurology
    Albert Einstein College of Medicine
    Bronx, NY

    Dr. Thorpy has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consultant/Advisory Board: Alkermes, Axsome, Balance Therapeutics, Eisai Pharmaceuticals, Flamel/Avadel, Harmony Biosciences, LLC, Idorsia Pharmaceuticals, Jazz Pharmaceuticals, NLS Pharmaceuticals, Suven Life Sciences Ltd., Takeda Pharmaceutical Co., Ltd, XWPharma

    Faculty:
    Anne Marie Morse, DO

    Director, Child Neurology and Pediatric
    Sleep Medicine, Geisinger Medical Center
    Janet Weis Children’s Hospital
    Danville, PA

    Dr. Morse has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Alkermes, Avadel Pharmaceuticals, Jazz Pharmaceuticals, Harm Reduction Therapeutics, Takeda Pharmaceutical Co.
    Research: Geisinger Health Plan, Jazz Pharmaceuticals, NIH, UCB,
    Other: DAMM Good Sleep, LLC

    Reviewers/Content Planners/Authors:

    • Jennifer Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Robert Schneider has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Delineate key differences among the clinical manifestations of narcolepsy symptoms in children versus adults
    • Define the physical, psychological, and social comorbidities associated with pediatric narcolepsy
    • Define the benefits and risks of current and evolving pharmacologic therapies that can optimize treatment outcomes for pediatric narcolepsy
  • Target Audience

    This activity is designed to meet the educational needs of the practicing sleep medicine specialist and pediatric neurologist.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until January 29, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Avadel CNS Pharmaceuticals, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free